Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

May 20, 2021

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

May 13, 2021

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.

May 12, 2021

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.

May 11, 2021

The quadruplet combination comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab was linked with high rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma.

May 10, 2021

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

May 03, 2021

Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.

April 28, 2021

Dickran G. Kazandjian, MD, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.

April 09, 2021

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

April 08, 2021

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

March 19, 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

March 18, 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

March 10, 2021

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

February 24, 2021

Jonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.

February 18, 2021

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

February 10, 2021

Aditi Dhir, MD, discusses risk-based stratification in patients with epithelioid and synovial sarcoma.

February 05, 2021

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

January 06, 2021

Aditi Dhir, MD, discusses modifying treatment for adults versus pediatric patients with epithelioid sarcoma.

January 04, 2021

Faculty of a recent Institutional Perspectives in Cancer webinar on sarcoma, hosted by Sylvester Comprehensive Cancer Center, share updates in the management of gastrointestinal stromal tumor, epithelioid and synovial sarcoma, and tenosynovial giant cell tumor.

November 19, 2020

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

November 05, 2020

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.